Biokilde ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  14.9% 11.3% 5.2% 5.3% 7.0%  
Credit score (0-100)  15 21 41 41 33  
Credit rating  BB BB BBB BBB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  270 1,587 1,085 1,581 25.2  
EBITDA  141 501 268 793 25.2  
EBIT  136 473 232 723 8.9  
Pre-tax profit (PTP)  135.0 442.3 211.7 723.1 32.0  
Net earnings  104.1 340.9 155.6 553.5 20.9  
Pre-tax profit without non-rec. items  135 442 212 723 32.0  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  77.5 124 158 126 12.2  
Shareholders equity total  74.1 415 571 797 1,054  
Interest-bearing liabilities  0.0 0.0 0.0 227 0.0  
Balance sheet total (assets)  726 3,369 4,103 2,952 1,206  

Net Debt  -2.4 -8.8 -932 227 0.0  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  270 1,587 1,085 1,581 25.2  
Gross profit growth  0.0% 488.8% -31.7% 45.8% -98.4%  
Employees  0 0 0 1 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% -100.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  726 3,369 4,103 2,952 1,206  
Balance sheet change%  0.0% 363.9% 21.8% -28.1% -59.1%  
Added value  140.6 500.9 267.7 758.6 25.2  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  73 18 -2 -102 -130  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  1.0 2.0 3.0 4.0 5.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  50.6% 29.8% 21.4% 45.7% 35.2%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  18.8% 23.1% 6.2% 20.9% 1.7%  
ROI %  177.0% 191.0% 46.7% 92.1% 3.4%  
ROE %  140.5% 139.4% 31.6% 80.9% 2.3%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  10.2% 12.3% 13.9% 27.0% 87.3%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -1.7% -1.8% -348.3% 28.7% 0.0%  
Gearing %  0.0% 0.0% 0.0% 28.5% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 11.7% 2.9%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  1.0 1.1 1.1 1.3 7.8  
Current Ratio  1.0 1.1 1.1 1.3 7.8  
Cash and cash equivalent  2.4 8.8 932.4 0.0 0.0  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  -0.4 294.5 417.0 671.4 1,041.4  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 759 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 793 0  
EBIT / employee  0 0 0 723 0  
Net earnings / employee  0 0 0 553 0